原发性胆汁性胆管炎治疗药物奥贝胆酸
发布时间：2018-11-11 13:00
【摘要】：原发性胆汁性胆管炎(PBC)是一种慢性肝内胆汁淤积性疾病,患者胆汁分泌受阻,从而损害肝细胞,引发肝纤维化和肝硬化。目前PBC的患病率不断升高,但约40%的患者对传统治疗药物熊去氧胆酸(UDCA)并不敏感,导致疾病进展风险升高。奥贝胆酸可有效治疗对UDCA反应不足或不耐受的患者,且治疗耐受性良好。本文对PBC的流行病学、最新治疗药物奥贝胆酸的药理学、毒理学以及临床安全性和有效性进行了概述。
[Abstract]:Primary biliary cholangitis (PBC) is a chronic intrahepatic cholestasis disease. The bile secretion of patients is blocked, which damages hepatocytes and leads to liver fibrosis and cirrhosis. At present, the prevalence of PBC is increasing, but about 40% of the patients are insensitive to the traditional drug ursodeoxycholic acid (UDCA), which leads to an increased risk of disease progression. Obercholic acid is effective in the treatment of patients who are insufficiently or intolerant to UDCA and are well tolerated. The epidemiology of PBC, pharmacology, toxicology, clinical safety and efficacy of the latest therapeutic drug Obercholic acid were reviewed.
【作者单位】： 江苏奥赛康药业股份有限公司;
【分类号】：R975
本文编号：2324915
[Abstract]:Primary biliary cholangitis (PBC) is a chronic intrahepatic cholestasis disease. The bile secretion of patients is blocked, which damages hepatocytes and leads to liver fibrosis and cirrhosis. At present, the prevalence of PBC is increasing, but about 40% of the patients are insensitive to the traditional drug ursodeoxycholic acid (UDCA), which leads to an increased risk of disease progression. Obercholic acid is effective in the treatment of patients who are insufficiently or intolerant to UDCA and are well tolerated. The epidemiology of PBC, pharmacology, toxicology, clinical safety and efficacy of the latest therapeutic drug Obercholic acid were reviewed.
【作者单位】： 江苏奥赛康药业股份有限公司;
【分类号】：R975
【相似文献】
相关硕士学位论文 前1条
1 莫利英;他喹莫德和奥贝胆酸的合成研究[D];浙江工业大学;2015年
，本文编号：2324915
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2324915.html
最近更新
教材专著
